Latest Share Purchase Plans News

Magellan Financial Group has announced a landmark merger with Barrenjoey Capital Partners, creating a diversified financial powerhouse valued at over A$1.6 billion. The deal includes a significant share placement and board reshuffle, setting the stage for expanded market influence.

FBR Limited reports a significant reduction in half-year losses alongside new robotic product launches, yet cash flow challenges raise questions about its financial sustainability.

PARKD Limited reported a 37% revenue decline to $3.88 million for H1 FY2026, driven by the winding down of its flagship Audi Centre Myaree project. The company posted a $1.03 million loss as it invests in East Coast growth and commissions a new prefabrication facility in Penrith, NSW.

Janus Electric Holdings reported a 46% increase in net loss to $4.93 million for the half-year ended December 2025, driven by rising costs despite a 33% revenue boost. The company faces funding uncertainties as it pursues key investments and operational scale-up.

Radiopharm Theranostics reported a 44% increase in net loss to $27 million for the half-year ended December 2025, driven by expanded R&D spending. The company bolstered its cash reserves through a $35 million placement while progressing multiple clinical trials across its radiopharmaceutical pipeline.

Mayfield Group Holdings Ltd has reported a striking 52.8% increase in revenue and a 127.6% jump in profit for the half-year ending December 2025, driven by manufacturing growth and strategic acquisitions.

Actinogen Medical has successfully completed a $16.8 million capital raising, combining a $12 million placement with a $4.8 million share purchase plan, to fund its pivotal Alzheimer’s disease trial and other 2026 initiatives.

HighCom Limited has revealed a sharp downturn in its half-year results, with revenue plunging 59% and a $6.8 million loss after tax, driven by US government shutdown impacts. The company is banking on new lightweight XTclave® armour products to fuel a recovery in the second half of FY26.

NOVONIX Limited posted a $92.7 million net loss for 2025 while progressing its synthetic graphite anode materials business and preparing to divest its Battery Technology Solutions segment.

Lynas Rare Earths Ltd has reported a striking half-year turnaround with a 1260% surge in net profit, underpinned by rising rare earth prices and strategic expansions. The company also completed a major equity raise to fuel its ambitious Towards 2030 growth plan.

Horizon Minerals has launched a Share Purchase Plan allowing eligible shareholders in Australia and New Zealand to buy additional shares between $2,000 and $30,000. The offer runs until 10 March 2026, with potential early closure depending on demand.

Cyclopharm Limited reported a 17% revenue increase to a record $32.3 million in 2025, powered by a 226% surge in US Technegas sales. The company is accelerating its US rollout with plans for up to 300 installations in 2026, while advancing clinical trials beyond pulmonary embolism.